

May 25, 2016

To,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai – 400 001

Scrip Code: 531099

Sub: Outcome of Board Meeting

Re: Financial Results for the Quarter and year ended March 31, 2016

Dear Sir(s),

With reference to the captioned subject, please find enclosed herewith, the Financial Results of the Company for the Quarter and Year Ended March 31, 2016 which was approved by the Board of Directors in their meeting held today i.e. May 25, 2016

Also attach is Limited Review Report for the year ended on March 31, 2016 given by the Statutory Auditor of the Company.

You are requested to take note of the same.

Thanking you,

Yours faithfully,

For **Rubra Medicaments Limited**



Mayuresh Tawde
Director
DIN – 01999743

RUBRA MEDICAMENTS LIMITED

Part I

(Rupees in Lacs)

Statement of Standalone Audited Results for the Quarter and Year ended 31/03/2016

Sr. No	Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in previous year	Current Year Ended	Previous year Ended
		31-Mar-16	31-Dec-15	31-Mar-15	31-Mar-16	31-Mar-15
		Audited	Unaudited	Unaudited	Audited	Audited
1	Income from operations					
	Net Sales/Income form Operations (Net of Excise Duty)	6.95	6.47	0.00	19.54	0.00
	Other Operating Income	0.00	0.00	0.00	0.00	0.00
	Total Income from Operations (Net)	6.95	6.47	0.00	19.54	0.00
2	Expenses					
a	Cost of Materials Consumed	0.00	0.00	0.00	0.00	0.00
b	Purchases of Stock-in-trade	5.45	5.08	0.00	12.59	0.00
c	Changes in Inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.42	0.00	0.00
d	Employee Benefit Expense	0.45	0.45	0.00	1.80	0.42
e	Depreciation and amortisation expenses	0.00	0.00	0.00	0.00	0.00
f	Other Expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	0.78	0.69	1.10	5.83	7.06
	Total Expenses	6.68	6.22	1.52	20.22	7.48
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	0.27	0.25	-1.52	-0.68	-7.48
4	Other Income	0.00	0.00	0.00	0.00	0.00
5	Profit / (Loss) from Ordinary activities before finance costs and exceptional items (3+4)	0.27	0.25	-1.52	-0.68	-7.48
6	Finance Cost	0.00	0.00	0.00	0.00	0.00
7	Profit / (Loss) from Ordinary activities after finance costs but before exceptional items (5+6)	0.27	0.25	-1.52	-0.68	-7.48
8	Exceptional Items	0.00	0.00	0.00	0.00	0.00
9	Profit / (Loss) from Ordinary activities before tax (7+8)	0.27	0.25	-1.52	-0.68	-7.48
10	Tax Expenses	0.00	0.00	0.00	0.00	0.00
11	Profit / (Loss) from Ordinary activities after tax (9+10)	0.27	0.25	-1.52	-0.68	-7.48
12	Extraordinary Items (net of tax expense)	0.00	0.00	0.00	0.00	0.00
13	Net Profit / (Loss) for the period (11+12)	0.27	0.25	-1.52	-0.68	-7.48
14	Share of Profit/(Loss) of associates	0.00	0.00	0.00	0.00	0.00
15	Minority Interest	0.00	0.00	0.00	0.00	0.00
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)	0.27	0.25	-1.52	-0.68	-7.48
17	Paid-up equity share capital (Face value of the Share is Rs.10/- each)	546.83	546.83	546.83	546.83	546.83
18	Reserves excluding Revaluation Reserves as per balance sheet) of previous accounting year				-508.43	-507.75
19.i	Earnings Per Share (EPS) (before Extraordinary items) of Rs. 10/- each (not to be annualized)					
	a) Basic	0.00	0.00	-0.03	-0.01	-0.14
	b) Diluted	0.00	0.00	-0.03	-0.01	-0.14
19.ii	Earnings Per Share (EPS) (after Extraordinary items) of Rs. 10/- (not to be annualized)					
	a) Basic	0.00	0.00	-0.03	-0.01	-0.14
	b) Diluted	0.00	0.00	-0.03	-0.01	-0.14
	Notes:					
1	The above results have been reviewed by the Audit Committee and taken on Record by the Board of Directors at its meeting held today					
2	The Segment-wise details are not applicable to the company as company has no segments.					

Date: May 25, 2016

Place: Mumbai


Managing Director

RUBRA MEDICAMENTS LIMITED
STATEMENT OF ASSETS AND LIABILITIES

A	EQUITY AND LIABILITIES	As on March 31, 2016	As on March 31, 2015
1	Shareholders Funds		
	(a) Share Capital	54,683,000	54,683,000
	(b) Reserves and Surplus	(50,842,784)	(50,774,820)
	(c) Money received against share warrants		
	Sub-total - Shareholders' funds	3,840,216	3,908,180
2	Share application money pending allotment	-	-
3	Minority interest	-	-
4	Non-current liabilities		
	(a) Long-term borrowings	-	-
	(b) Deferred tax liabilities (net)	746,257	746,257
	(c) Other long-term liabilities		-
	(d) Long-term provisions		-
	Sub-total - Non-current liabilities	746,257	746,257
5	Current liabilities		
	(a) Short-term borrowings	-	-
	(b) Trade payables	-	-
	(c) Other current liabilities	-	-
	(d) Short-term provisions	-	-
	Sub-total - Current liabilities	-	-
	TOTAL - EQUITY AND LIABILITIES	4,586,473	4,654,437
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	-	-
	(b) Goodwill on consolidation	-	-
	(c) Non-current investments	-	-
	(d) Deferred tax assets (net)	-	-
	(e) Long-term loans and advances	3,282,070	3,054,070
	(f) Other non-current assets	168,819	168,819
	Sub-total - Non-current assets	3,450,889	3,222,889
2	Current Assets		
	(a) Current investments	-	-
	(b) Inventories	-	-
	(c) Trade receivables	177,269	177,269
	(d) Cash and cash equivalents	958,315	1,254,279
	(e) Short-term loans and advances		-
	(f) Other current assets		-
	Sub-total - Current assets	1,135,584	1,431,548
	TOTAL - ASSETS	4,586,473	4,654,437



**Report On Quarterly Financial Results and Year to Date Results of the Company
Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015**

To,
Board of Directors
Rubra Medicaments Limited

We have audited the quarterly financial results of Rubra Medicaments Ltd for the quarter ended March 31, 2016 (date of the quarter end) and the year to date results for the period April 1, 2015 to March 31, 2016, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25 / Ind AS 34), prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued there under; or by The Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

(i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and

(ii) give a true and fair view of the net profit/ loss and other financial information for the quarter ended March 31, 2016 (date of the quarter end) as well as the year to date results for the period from April 1, 2015 to March 31, 2016

For Prakash Modi & Associates
Chartered Accountants
FRN: 116900W

Prakash Modi

Prakash Modi
Partner
M. No. 101463




Place: Mumbai
Date: May 25, 2016

Form A


Covering Letter of the Annual Audit Report to be filed with the stock exchanges

1.	Name of the Company	Rubra Medicaments Limited
2.	Annual Financial Statements for the year ended	March 31, 2016
3.	Type of Audit Observation	Un-Qualified
4.	Frequency of Observation	NA


For Rubra Medicaments Limited


Mayuresh Tawde
Whole Time Director

For Rubra Medicaments Limited


Dinesh Nayak
Chairman - Audit Committee

For Prakash Modi & Associates
Chartered Accountants
FRN: 116900W



CA Prakash Modi
Partner
M. No. 101463



Date: May 25, 2016

Place: Mumbai